Efficiency of Sunitinib in Chinese Patients with Advanced Progressive Pancreatic Neuroendocrine Tumor.
10.3881/j.issn.1000-503X.2016.03.010
- Author:
He-li GAO
1
;
Hong-yan YING
1
;
Yue-juan CHENG
1
;
Chang-ting MENG
1
;
Chun-mei BAI
1
Author Information
1. Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Disease-Free Survival;
Humans;
Indoles;
therapeutic use;
Pancreatic Neoplasms;
drug therapy;
Pyrroles;
therapeutic use
- From:
Acta Academiae Medicinae Sinicae
2016;38(3):300-304
- CountryChina
- Language:English
-
Abstract:
Objective To explore the efficiency of sunitinib in Chinese pancreatic neuroendocrine tumors (pNET) patients. Methods Advanced pNET patients who had accepted sunitinib treatment in the oncology department of PUMC Hospital from January 2009 to June 2015 after disease progression were enrolled in this study. Data collection included clinicopathological characteristics,medical therapies and outcomes. Results Eighteen pNET patients were collected. The overall response rate (ORR) was 27.7% and the disease control rate (DCR) was 83.3%. Nine patients received sunitinib as the first-line therapy and 9 as the second/post-second line. The median progression-free survival (mPFs)(12 month vs. 12 month;HR:0.92,95%CI:0.31-2.75,P=0.88),ORR (22.2% vs.33.3%;Χ(2)=0.055,P=0.98),and DCR (88.9% vs.77.8%;Χ(2)=0.4,P=0.98)showed no significant difference between first-line therapy and post-second line therapy. The mPFS of Ki-67≥10% and Ki-67<10% group patients was not significantly different (8 months vs. 13 months;HR:1.13,95% CI:0.34-3.77,P=0.845). The commonly reported adverse events included bone marrow suppression,diarrhea,roteinuria,hypertension,and rash. Conclusions First-line or second/post-second line sunitinib treatment has certain antitumor activity in Chinese patients with advanced pNET. The efficiency and commonly reported adverse events of Sunitinib are consistent with the known Western data.
